Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 218

Similar articles for PubMed (Select 23178691)

1.

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.

Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Jun;19(7):877-84. doi: 10.1177/1352458512466929. Epub 2012 Nov 24.

PMID:
23178691
2.

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.

Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD.

Neurology. 2009 Apr 14;72(15):1322-9. doi: 10.1212/WNL.0b013e3181a0fe3f.

PMID:
19365053
3.

Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

Khademi M, Dring AM, Gilthorpe JD, Wuolikainen A, Al Nimer F, Harris RA, Andersson M, Brundin L, Piehl F, Olsson T, Svenningsson A.

PLoS One. 2013 May 7;8(5):e63172. doi: 10.1371/journal.pone.0063172. Print 2013.

4.

Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.

Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I, Paolino E, Granieri E, Dallocchio F.

Mult Scler. 2006 Jun;12(3):294-301.

PMID:
16764342
5.

Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.

Guimarães I, Cardoso MI, Sá MJ.

Mult Scler. 2006 Jun;12(3):354-6.

PMID:
16764350
6.

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Romme Christensen J, Börnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, Sørensen PS, Sellebjerg F.

PLoS One. 2013;8(3):e57820. doi: 10.1371/journal.pone.0057820. Epub 2013 Mar 1.

7.

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.

Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T.

J Proteomics. 2010 Apr 18;73(6):1117-32. doi: 10.1016/j.jprot.2010.01.004. Epub 2010 Jan 20.

PMID:
20093204
8.

Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.

Obradović D, Kataranovski M, Dincić E, Obradović S, Colić M.

Vojnosanit Pregl. 2012 Feb;69(2):151-6.

PMID:
22500369
9.

Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.

Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA.

Exp Neurol. 2014 Nov;261:620-32. doi: 10.1016/j.expneurol.2014.07.020. Epub 2014 Aug 8.

PMID:
25111532
10.

Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.

Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, Trentini A, Killestein J, Nielsen J, Vrenken H, Popescu V, Dijkstra CD, Jimenez CR.

Mult Scler. 2011 Jul;17(7):838-50. doi: 10.1177/1352458511399614. Epub 2011 Apr 19.

PMID:
21505015
11.

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A.

Mult Scler. 2014 Jan;20(1):43-50. doi: 10.1177/1352458513490544. Epub 2013 May 23.

PMID:
23702432
12.

Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.

Verbeek MM, Notting EA, Faas B, Claessens-Linskens R, Jongen PJ.

Acta Neurol Scand. 2010 May;121(5):309-14. doi: 10.1111/j.1600-0404.2009.01242.x. Epub 2009 Nov 19.

PMID:
19925532
13.

Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.

Elovaara I, Ukkonen M, Leppäkynnäs M, Lehtimäki T, Luomala M, Peltola J, Dastidar P.

Arch Neurol. 2000 Apr;57(4):546-51.

PMID:
10768630
14.

Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis.

Modvig S, Degn M, Horwitz H, Cramer SP, Larsson HB, Wanscher B, Sellebjerg F, Frederiksen JL.

PLoS One. 2013 Oct 8;8(10):e77163. doi: 10.1371/journal.pone.0077163. eCollection 2013.

15.
16.

Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.

Takahashi K, Kurihara Y, Suzuki Y, Goshima Y, Tanaka F, Takei K.

JAMA Neurol. 2015 Feb;72(2):176-9. doi: 10.1001/jamaneurol.2014.3613.

PMID:
25437093
17.

Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.

Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, Malmeström C, Lycke J, Blennow K, Zetterberg H, Mattsson N.

Mult Scler. 2013 Apr;19(5):543-52. doi: 10.1177/1352458512460603. Epub 2012 Oct 15.

PMID:
23069872
18.

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J.

J Neurol. 2011 May;258(5):882-8. doi: 10.1007/s00415-010-5863-2. Epub 2011 Jan 1.

PMID:
21197541
19.

Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.

Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, Murai H, Kira J.

PLoS One. 2013 Apr 18;8(4):e61835. doi: 10.1371/journal.pone.0061835. Print 2013.

20.

Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.

Wullschleger A, Kapina V, Molnarfi N, Courvoisier DS, Seebach JD, Santiago-Raber ML, Hochstrasser DF, Lalive PH.

PLoS One. 2013 Aug 27;8(8):e72399. doi: 10.1371/journal.pone.0072399. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk